New treatment strategies for inflammatory bowel disease using PD1 agonists
Development of novel PD1 agonist therapeutic strategies for inflammatory bowel disease
This study is exploring new ways to help people with inflammatory bowel disease (IBD) by using special treatments that boost the immune system to reduce inflammation and improve their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11015851 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapeutic strategies for inflammatory bowel disease (IBD) by enhancing the PD1 signaling pathway, which plays a crucial role in regulating immune responses. The approach involves using PD1 agonists to promote the stability and induction of regulatory T cells, which are essential for maintaining immune tolerance and preventing excessive inflammation. By combining low-dose interleukin-2 with PD1 agonists, the researchers aim to create a synergistic effect that could improve treatment outcomes for patients with IBD. The study will involve preclinical models to test the effectiveness of these new strategies in controlling bowel inflammation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who are seeking new treatment options.
Not a fit: Patients with non-autoimmune gastrointestinal disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for inflammatory bowel disease, improving long-term immune balance and reducing inflammation in patients.
How similar studies have performed: Previous research has shown promise in enhancing PD1 signaling for autoimmune conditions, indicating potential for success with this novel approach.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Gopal, Murugaiyan — Brigham and Women's Hospital
- Study coordinator: Gopal, Murugaiyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.